boxkid

Trending

Recently Published

Heading to Florida for NASA's Artemis 2 moon launch? Here's what to know before you go

Heading to Florida for NASA's Artemis 2 moon launch? Here's what to know before you go

Factbox-Artemis II crew includes first woman, Black astronaut and Canadian ever flown to moon

Factbox-Artemis II crew includes first woman, Black astronaut and Canadian ever flown to moon

Illegal entries into Germany halve over two years, border police say

Illegal entries into Germany halve over two years, border police say

Are multiverses real? An astrophysicist explains why it depends on how you define ‘real’

Are multiverses real? An astrophysicist explains why it depends on how you define ‘real’

Ancient eggshells shed new light on crocodiles that hunted prey from trees

Ancient eggshells shed new light on crocodiles that hunted prey from trees

Recommend articles

A Republican elected governor in California? It's not as far-fetched as it sounds.

A Republican elected governor in California? It's not as far-fetched as it sounds.

Robyn returns to music with 'Dopamine,' her 1st single in 7 years: 'Came to save music once again'

Robyn returns to music with 'Dopamine,' her 1st single in 7 years: 'Came to save music once again'

Robyn's new single "Dopamine" has arrived.

A photographer's journey to capture a blood moon rising over the South China Sea. 'It was an incredible moment'

A photographer's journey to capture a blood moon rising over the South China Sea. 'It was an incredible moment'

"For a brief instant, I simply stood there, stunned. Then instinct took over".

Shah Capital pushes for Novavax sale, warns of proxy fight

Shah Capital pushes for Novavax sale, warns of proxy fight

By Sneha S K and Sriparna Roy (Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no progress ‌is made in the next four months. In a second letter to Novavax's board in less than a month, shared exclusively with ‌Reuters on Wednesday, Shah Capital said it has become "increasingly disenchanted" with the company's weak COVID-19 vaccine sales.